Test Price
2,800 AED✅ Home Collection Available
AMPD2 Gene SPG63 Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين AMPD2 لمرض SPG63 بتقنية التسلسل المتقدم NGS في الإمارات | 2800 درهم | إرشادات هيئة الصحة بدبي 2026
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO‑accredited Next‑Generation Sequencing in our UAE‑licensed facility.
- Premium Logistics: Paid Hospital‑Grade Home Collection via ISO‑certified Cold‑Chain Home Collection, and VIP Mobile Phlebotomy service (8 AM‑11 PM).
- Clinical Guidance: Complimentary Telephonic Post‑Test Clinical Guidance to interpret results and coordinate with your neurologist.
- Insurance Support: Direct Billing Verification via WhatsApp +971 54 548 8731.
ملخص تنفيذي
يقدم اختبار الجين AMPD2 بتقنية التسلسل الجيني المتقدم (NGS) تشخيصًا دقيقًا لاضطراب الشلل النصفي التشنجي الوراثي من النوع 63 (SPG63). يتم التحليل في مختبر معتمد وفق معيار ISO 9001:2015 بضمان دقة تفوق 99.9%، مع إمكانية سحب العينة منزليًا عبر خدمة التمريض المتنقل المبرّد. يلتزم الإجراء بقوانين دولة الإمارات والخصوصية الوراثية، ويوفر إرشادًا سريريًا هاتفيًا مجانيًا بعد النتيجة.
Test Overview
The AMPD2 SPG63 Genetic Test uses next‑generation sequencing to detect pathogenic variants in the AMPD2 gene, confirming hereditary spastic paraplegia type 63 (SPG63) – a rare neurological disorder. يُحدد التحليل الطفرات المسببة للمرض في جين AMPD2 بدقة عالية، مما يتيح وضع خطة علاجية مبكرة. Results are returned within 3‑4 weeks with full clinical interpretation.
| Parameter | Our NGS AMPD2 Test | Closest Alternative (Single‑Gene Sanger) |
|---|---|---|
| Precision | Full gene coverage, detects point mutations, deletions/duplications, and novel variants | Limited to known mutation hot‑spots only |
| Method | Next‑Generation Sequencing (NGS) with bioinformatic verification | Sanger sequencing of selected exons |
| Speed | 3‑4 weeks with comprehensive report | 6‑8 weeks, often requires reflex testing |
Physician Insight & Safety Protocol
“As a neurologist dedicated to rare movement disorders, I emphasise that a positive AMPD2 result must be integrated with clinical examination and family history. Never interpret this test in isolation; genetic counselling is essential. This NGS assay meets the highest evidence standards, but your personal story is the most valuable piece of the puzzle.”
— Dr. PRABHAKAR REDDY, DHA License 61713011
Medication Warning:
Do not discontinue prescribed medication without consulting your doctor. This genetic test does not replace ongoing neurological management.
Exclusion Criteria & Emergency Red Flags
Exclusion Criteria
- Inability to provide informed consent (as per Federal Decree‑Law No. 41 of 2024 and UAE PDPL).
- Patient without a clinical indication for genetic testing, as determined by a neurologist or clinical geneticist.
- Recent (within 3 months) allogeneic bone marrow transplant or blood transfusion that may interfere with DNA analysis.
Red Flags – Seek Immediate Care
- Rapidly progressing leg weakness or spasticity with loss of ambulation before receiving results.
- Development of seizures, sudden vision loss, or severe cognitive decline.
- Any acute neurological emergency – proceed to the nearest hospital; do not wait for test results.
Frequently Asked Questions
1. What is the AMPD2 SPG63 genetic test and why is it important?
The AMPD2 SPG63 NGS test identifies disease‑causing mutations in the AMPD2 gene to confirm hereditary spastic paraplegia type 63, enabling early intervention. This rare neurodegenerative condition affects walking and coordination, and a precise genetic diagnosis helps tailor physical therapy, medications, and family planning. Our test uses next‑generation sequencing to read the entire coding region, offering the highest diagnostic yield.
يقوم اختبار AMPD2 SPG63 بتقنية التسلسل المتقدم بتحديد الطفرات المرضية في جين AMPD2 لتأكيد تشخيص الشلل النصفي التشنجي الوراثي من النوع 63، مما يساعد في التدخل المبكر وتخطيط العناية السريرية.
2. How is the test performed and what sample is required?
A simple blood draw, extracted DNA, or a single drop of blood on an FTA card is collected by our licensed phlebotomist during a home visit. Once in our ISO‑certified lab, DNA is extracted and sequenced using NGS. You must complete a pre‑test genetic counselling session to document family history, as required by UAE law for genetic testing.
يتم جمع عينة دم بسيطة أو حمض نووي مستخلص أو قطرة دم على بطاقة FTA بواسطة ممرض مرخص خلال زيارة منزلية، ثم يتم تسلسل الجين باستخدام تقنية NGS في مختبرنا المعتمد.
3. What do my results mean and what follow‑up is required?
A positive report indicates a confirmed genetic diagnosis of SPG63; your neurologist will discuss prognosis, symptomatic management, and family screening. Negative results may still require further testing if clinical suspicion remains. We provide a complimentary post‑ tele‑consultation to explain findings and coordinate with your treating physician. All data is protected under UAE PDPL regulations.
تؤكد النتيجة الإيجابية التشخيص الجيني لمرض SPG63، ويقوم الطبيب المختص بشرح الخطة العلاجية وفحص أفراد الأسرة المعرضين للخطر.
Compliant with Federal Decree‑Law No. 41 of 2024 (Art. 87), CDS Law 2026 (Minor Consent), UAE PDPL Data Privacy.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians